Skip to main content
Main navigation
Home
About pCPA
Who We Are
Governance
FAQs
Negotiations
Recent Updates
Forms and Publications
Brand Name Drugs
Negotiations Status
Negotiation Process
Generic Drugs
Biologics/Biosimilars
Contact Us
EN
FR
Januvia (sitagliptin phosphate)
pCPA File Number:
21084
Negotiation Status:
Concluded with an LOI
Indication(s):
Diabetes Mellitus, Type 2
Sponsor/Manufacturer:
Merck Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
2018-11-02
Negotiation Process Concluded:
2020-03-10